Capital CS Group’s iShares Biotechnology ETF IBB Stock Holding History

Capital CS Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$584K	Buy	+2,773	New	+$556K	0.43%	35

Other funds holding IBB

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

WestEnd Advisors Charlotte, North Carolina $4.53B AUM 12.98% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.92% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return

Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return

Capital CS Group's IBB Position: Q3 2026 in Review

Capital CS Group opened a new position in iShares Biotechnology ETF (IBB) in Q3 2026: 2,773 shares worth $584K. The stake represents 0.43% of the portfolio and ranks #35 among its holdings.

603 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

Capital CS Group held 2,773 shares of iShares Biotechnology ETF worth $584K as of Q3 2026.
iShares Biotechnology ETF was a new Capital CS Group position in Q3 2026.
iShares Biotechnology ETF made up 0.43% of Capital CS Group's portfolio in Q3 2026, its #35 holding.
603 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Capital CS Group's 13F filing for Q3 2026, filed 29 Oct 2026.